Apollo Circles J&J's Orthopedics Unit in Carve-Out Talks

Apollo Global Management Inc. is in discussions to acquire Johnson & Johnson's orthopedics business, a unit the healthcare conglomerate has been working to separate, according to people familiar with the matter reported by Bloomberg on Sept. 11, 2026.

Apollo Global Management Inc. (APO) is in talks to buy the orthopedics business that Johnson & Johnson (JNJ) has been preparing to separate from the rest of the company, according to people familiar with the discussions. The talks were reported by Bloomberg Industries. No price, structure or timetable has been disclosed, and there is no confirmation from either company that a transaction will result.

The shape of the conversation matters more than the absence of a headline number. A separation that had been framed largely as a corporate housekeeping exercise — spin, split, or sale — now has a named private-capital bidder attached to it. That changes the range of outcomes for employees, for hospital customers, and for shareholders on both sides of the table.

Why J&J wanted the unit out in the first place

Orthopedics is a durable business but a structurally different one from the rest of what Johnson & Johnson does. Hips, knees, trauma plates, spine hardware and the instrument trays that go with them are capital-heavy, sales-rep-intensive and priced against hospital purchasing committees that grind margins down over time. Pharmaceuticals, by contrast, live on patent cliffs and clinical readouts. Running both under one roof means one set of investors is always being asked to underwrite a business they did not come for.

That is the usual logic behind a separation, and it is the logic J&J has already applied elsewhere in its portfolio. Stripping out a slower-growth device franchise lifts the reported growth rate of what remains, sharpens the capital allocation story, and frees management attention for the parts of the business where returns compound faster.

The open question has always been the exit route. A spin-off hands the problem to public shareholders and gives the new company a currency of its own. A sale converts the unit into cash today. Apollo's involvement points at the second path — and at a buyer that would take on the operational rebuild without a quarterly earnings audience watching every step.

What a carve-out gives Apollo

Large corporate carve-outs are one of the few deal types in private equity where scale is an advantage rather than a handicap. The work is unglamorous: standing up separate IT, supply chain, regulatory and quality systems that had been shared with a parent; renegotiating hospital contracts under a new legal entity; keeping surgeons and sales forces from drifting to competitors during the transition. Firms without the balance sheet and the operating bench to do that simply cannot bid.

For an alternative asset manager, a business like this also fits the shape of capital being raised today. Medical device revenue is recurring, procedure volumes are demographically supported by an aging population, and the cash flows are predictable enough to carry debt — which is precisely the profile that private credit and insurance-linked capital want to lend against.

None of that guarantees a deal. Carve-out talks routinely break down over the transition services agreement, over how shared manufacturing sites are divided, or over liabilities that neither side wants to keep. Talks reported through people familiar with the matter are, by definition, not signed documents.

How the two stocks stand going into the story

Neither share price has priced in a completed transaction, because there is nothing yet to price. As of the last trade on Friday, Sept. 11, 2026 at 20:00 GMT, Apollo closed at 128.98, up 0.84% on the day from a prior close of 127.91, having traded between 128.24 and 131.22. Johnson & Johnson closed at 265.58, down 0.29% from a prior close of 266.35, with a day range of 265.25 to 270.40.

The J&J move was a mild drift lower on a day when the broad market was firmly higher. The S&P 500, as tracked by SPY, closed at $764.29, up 0.85%. The Nasdaq 100 proxy QQQ closed at $714.88, up 0.87%, and the Dow 30 proxy DIA at $525.79, up 0.97%. So J&J underperformed a rising tape while Apollo roughly matched it — hardly a verdict on the deal, but worth noting that the buyer, not the seller, held up better on the day the talks surfaced.

Both names also closed well below their intraday highs. Apollo gave back ground from 131.22, and J&J from 270.40. That pattern of fading into the close is common on days when a report lands late in the session and traders would rather not carry a position into the weekend on an unconfirmed story.

What decides whether this gets done

Three things will determine the outcome, and none of them are visible from the outside yet.

• Price against the spin alternative. A board only sells when cash today beats the modelled value of an independent company tomorrow, after separation costs. If Apollo's number does not clear that bar, J&J can simply proceed with the separation it was already pursuing.
• Financing. A device business of this scale requires a large debt package. The terms available in the leveraged loan and private credit markets when the talks reach the signing stage will move the price a buyer can justify.
• Regulatory and customer risk. Orthopedic implants are heavily regulated and heavily concentrated among a handful of suppliers. Antitrust review is less of an obstacle for a financial buyer than for a strategic one, which is part of why private capital gets a seat at these tables — but quality-system continuity and hospital contract novation still take time.

For J&J shareholders, the practical read is that a credible buyer raises the floor under the separation. Even if Apollo walks, the existence of a bid gives the board leverage and a reference valuation. For Apollo shareholders, the read is about deployment: a transaction of this size would be a meaningful use of committed capital and a test of the firm's ability to run a clinical-grade manufacturing operation rather than simply own one.

What to watch next

The first confirmable signal will be a statement from either company — or, more likely, a pointed refusal to comment. After that, watch for the named structure of the separation. If J&J continues to describe the unit's future in spin-off language, the sale track is probably cool. If the language shifts toward "strategic alternatives," an auction is live and other sponsors will surface.

Also worth tracking: whether competing bidders emerge. Carve-outs of this profile rarely stay bilateral once a report reaches the tape. A single named suitor in a Friday evening story is frequently the opening of a process rather than the end of one.

Until either company speaks, everything beyond the fact of discussions is inference. The verified facts are narrow: Apollo is talking, J&J wants the unit out, and no terms have been made public.

Key facts

• APO last close: 128.98, +0.84% (Sept. 11, 2026, 20:00 GMT)
• JNJ last close: 265.58, -0.29% (Sept. 11, 2026, 20:00 GMT)
• Deal status: Talks only; no price, structure or timetable disclosed
• Asset in play: Johnson & Johnson's orthopedics unit, which J&J has sought to separate

Frequently asked questions

What exactly was reported about Apollo and Johnson & Johnson?

Bloomberg reported on Sept. 11, 2026 that Apollo Global Management Inc. is in discussions to acquire the orthopedics unit that Johnson & Johnson has been looking to separate from the rest of the company. The report cited people familiar with the matter. No purchase price, deal structure or timetable was disclosed, and neither company has confirmed a transaction.

Has a deal been agreed?

No. What has been reported is discussions, sourced to people familiar with the matter. Talks of this kind frequently end without a transaction, particularly in corporate carve-outs where separation costs, transition services arrangements and the allocation of shared manufacturing assets can stall negotiations. Until either company issues a statement, no terms should be treated as settled.

How did the two stocks close on the day of the report?

Apollo closed at 128.98, up 0.84% from a prior close of 127.91, with a day range of 128.24 to 131.22. Johnson & Johnson closed at 265.58, down 0.29% from a prior close of 266.35, with a day range of 265.25 to 270.40. Both figures are as of the last trade at 20:00 GMT on Sept. 11, 2026.

Why would J&J want to separate its orthopedics business?

Orthopedics is capital-intensive, sales-force-heavy and priced against hospital purchasing committees, giving it a different margin and growth profile from pharmaceuticals. Separating it lifts the reported growth rate of the remaining business, simplifies capital allocation and lets management concentrate on higher-return segments. It is the same rationale behind most large healthcare portfolio separations.

Why do private equity firms target corporate carve-outs?

Carve-outs let a buyer acquire an established business at a discount to its standalone potential, because the unit has been run as a non-core division. The buyer then builds independent IT, supply chain and regulatory systems. The work is complex and expensive, so only firms with substantial balance sheets and operating teams can realistically bid for assets of this scale.

What should investors watch from here?

Watch for any confirmation or refusal to comment from either company, and for a shift in how J&J describes the unit's future — spin-off language versus 'strategic alternatives,' which signals a live auction. Also watch for competing bidders, since carve-outs of this profile rarely stay bilateral once reported, and for the debt financing terms available to any buyer.

Sources

• Apollo Global Is Said in Talks to Acquire J&J’s Orthopedics Unit — Bloomberg Industries

Photo: cottonbro studio · Pexels Licence — source